Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02851277 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
A Phase 1 study of Peanut Allergy, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 8
- Study locations
NCT02851277: Completed Phase 1 study of Peanut Allergy, sponsored by Astellas Pharma Global Development.
NCT02851277 is a Phase 1 study of Peanut Allergy that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 31 participants, below the 212-participant average among 13 other Peanut Allergy trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02851277, a Phase 1 study of Peanut Allergy, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal or intramuscular injection in adults with peanut allergy.
Conditions Studied
Interventions
- DRUG ASP0892 Intradermal
- DRUG ASP0892 Intramuscular
- DRUG Placebo Intradermal
- DRUG Placebo Intramuscular
Study Locations (8)
Arkansas
- Site US10014 - Little Rock
California
- Site US10008 - Mountain View
Maryland
- Site US10001 - Baltimore
Massachusetts
- Site US10002 - Boston
New York
- Site US10004 - New York
North Carolina
- Site US10003 - Chapel Hill
Ohio
- Site US10012 - Cincinnati
Washington
- Site US10006 - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2018-12-06 |
| Phase | Phase 1 |
What the finished NCT02851277 record still lists
NCT02851277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 212-participant average among 13 other Peanut Allergy trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 4 interventions - of which ASP0892 Intradermal is the first listed.
NCT02851277 lists 8 locations in 8 states (Arkansas, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT02851277 about?
NCT02851277 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine". The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal or intramuscular injection in adults with peanut allergy.
What is the current status of trial NCT02851277?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2016-12-13. Estimated completion is 2018-12-06.
What conditions does trial NCT02851277 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT02851277?
The interventions under investigation include: ASP0892 Intradermal (DRUG), ASP0892 Intramuscular (DRUG), Placebo Intradermal (DRUG), Placebo Intramuscular (DRUG).
Who is sponsoring clinical trial NCT02851277?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02851277 being conducted?
This trial has 8 study locations across Arkansas, California, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02851277's enrollment target sits among peer trials
31 14th of 13 the lowest of 13 other Peanut Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peanut Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ACTIVE NOT RECRUITING · Phase 1
-
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
COMPLETED · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI